Competitive DRUGS Act of 2017

Fact Sheet

Bill Number

HR 4117

Introduced

Oct 25, 2017

Latest Action

Referred to the Subcommittee on Digital Commerce and Consumer Protection.

Sponsor

Cosponsors

Topics

Administrative remedies Business expenses Civil actions and liability Competition and antitrust Federal Trade Commission (FTC) Health Income tax deductions Intellectual property Judicial review and appeals Marketing and advertising Prescription drugs Research and development

Full Text

View Full Bill Text

Votes

Summary

Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017

This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.

Actions

Oct 27, 2017

Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Oct 25, 2017

Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 25, 2017

Introduced in House

Amendments

Related Bills